Signal Explorer
10-K · 10-Q · 8-K · last 6 months · ← back to feed
MYRIAD GENETICS INC
MYGN
Core
Management Exodus
Other
Rsu Psu Vesting Schedule Disclosed
Goodwill Impairment
Impairment Charge Breakdown
Covenant Compliance Affirmation
Effective Tax Rate Reconciliation
Quarterly Tax Provision Benefit Disclosure
Equity Plan Board Approval Conditional On Shareholder Vote
Share Repurchase Activity Disclosed
Equity Plan Share Reserve Disclosure
Libor Based Term Loan Pricing
Event Of Default Defined
Ai Diagnostics Investment
Liquidity Position Snapshot Disclosed
Weighted Average Interest Rate Disclosed
Healthcare
Reimbursement Improving
Other
Net Loss Reported
Ai Diagnostics Investment
Gross Margin Comparison Disclosed
Interim Data Positive
Publication Positive
Kol Endorsement
Liquidity Position Snapshot Disclosed
Goodwill Impairment
Patient Retention High
Core
Clinical Trial Result
Combination Therapy Mentioned
Secondary Endpoint Mentioned
Healthcare
Utilization Improving
Core
Management Exodus
Other
Auditor Appointment Ratification
Classified Board Director Election
Equity Plan Share Reserve Disclosure
Other
Goodwill Impairment
Use Of Proceeds Disclosure
Reimbursement Price Pressure Risk
Effective Tax Rate Reconciliation
Codm Segment Reporting Disclosure
Covenant Compliance Affirmation
Equity Plan Board Approval Conditional On Shareholder Vote
Share Repurchase Activity Disclosed
Libor Based Term Loan Pricing
Equity Plan Share Reserve Disclosure
Impairment Charge Breakdown
Advertising Cost Disclosure
Deferred Tax Asset Valuation Disclosure
Quarterly Tax Provision Benefit Disclosure
Healthcare
Reimbursement Improving
Biotech Risk
Accelerated Approval
Other
Net Loss Reported
Ai Diagnostics Investment
Gross Margin Comparison Disclosed
Liquidity Position Snapshot Disclosed
Ce Mark Received
Interim Data Positive
Kol Endorsement
Core
Clinical Trial Result
Indication Expansion
Healthcare
Reimbursement Improving
Same Facility Growth
Volume Inflecting
SaaS
Billings Acceleration
Same Client Revenue Growing